Abstract Atherosclerotic cardiovascular disease (CVD) is a collective term comprising of a group of disorders of the heart and blood vessels. These diseases are the largest cause of morbidity and premature death worldwide. Coronary heart disease and cerebrovascular disease (stroke) are the most frequently occurring diseases. The two major initiators involved in the development of atherosclerotic CVD are vascular production of reactive oxygen species (ROS) and lipid oxidation. In atherosclerosis development, ROS is associated with rapid loss of anti-inflammatory and anti-atherogenic activities of the endothelium-derived nitric oxide (NO Á ) resulting in endothelial dysfunction. In part involving activation of the transcription factor NF-jB, ROS have been involved in signaling cascades leading to vascular pro-inflammatory and pro-thrombotic gene expression. ROS is also a potent activator of matrix metalloproteinases (MMPs), which indicate plaque destabilization and rupture. The second initiator involved in atherosclerotic CVD is the oxidation of low-density lipoproteins (LDL). Oxidation of LDL in vessel wall leads to an inflammatory cascade that activates atherogenic pathway leading to foam cell formation. The accumulation of foam cells leads to fatty streak formation, which is the earliest visible atherosclerotic lesion. In contrast, the cardiac sarco/endoplasmic reticulum Ca 2? -ATPase (SERCA2a) and hepatic apolipoprotein E (apoE) expression can improve cardiovascular function. SERCA2a regulates the cardiac contractile function by lowering cytoplasmic calcium levels during relaxation, and affecting NO Á action in vascular cells, while apoE is a critical ligand in the plasma clearance of triglyceride-and cholesterol-rich lipoproteins.
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Introduction
Atherosclerotic cardiovascular disease (CVD) is the leading cause of death in the United States and industrialized countries (Trogdon et al. 2007) . It is estimated that more than 80 % of all CVD mortality now occurs in developing countries (Perk et al. 2012) . CVD is a chronic disorder developing insidiously throughout life and usually progresses to an advanced stage by the time symptoms occur.
The most frequent diseases of CVD are coronary heart disease (CHD) and cerebrovascular disease (stroke), whereas CHD remains the leading cause of premature death worldwide (Perk et al. 2012) . Important evidence demonstrated that reactive oxygen species (ROS) and oxidative stress are important features of CVD including atherosclerosis, hypertension, and congestive heart failure (Sugamura and Keaney 2011) . Likewise, the oxidation of lipoproteins indicated a major risk factor in the development of atherosclerosis (Steinberg 2002) . This review discusses the role of oxidative stress and lipoprotein oxidation as initiators ''the underlying causes'' of CVD, in addition to describing the protective role of SERCA2a and hepatic apolipoprotein E expression in improving cardiovascular function.
Reactive oxygen species (ROS)
ROS is a collective term that includes both oxygen radicals, such as superoxide (O 2
Á2
), hydroxyl radicals (OH Á ), peroxyl (RO 2 Á ), and hydroperoxyl (HO 2 Á ) radicals, and certain non-radical oxidizing agents such as hydrogen peroxide (H 2 O 2 ), hydrochlorous acid (HOCl), and ozone (O 3 ), which are easily converted to free radicals (highly active unpaired electrons). Accordingly, some of these species are extremely unstable, such as superoxide and hydroxyl radicals, whereas others are freely diffusible and relatively long-lived (Finkel and Holbrook 2000) .
Role of oxidative stress in cardiovascular disease
Over the last decades, it has become increasingly clear that ROS, including free radicals, are involved in CVD. ROS participate in normal cell signaling as mediators that regulate vascular function. In the vascular wall, ROS are produced by all layers including endothelium, smooth muscle, and adventitia (Lakshmi et al. 2009 ). The experimental and clinical studies in patients with CVD like coronary disease, hypertension, smoking, or diabetes indicated that there is a relationship between cardiovascular risk factors and the increased vascular production of ROS (Hink et al. 2001) . In physiological view, ROS are produced in low concentrations and act as signaling molecules that regulate vascular smooth muscle cell contraction and relaxation (Rao and Berk 1992) . In pathophysiological view, these free radicals play important roles in the development of disorders including atherosclerosis, arrhythmia, cardiomyopathy, congestive heart failure, ischemic heart disease, diabetes, and cancer (Zalba et al. 2001) . In humans, increased oxidative stress has been demonstrated in patients with cardiovascular risk factors through excessive levels of F 2 isoprostanes, stable, free radicalcatalyzed products of arachidonic acid reflecting lipid peroxidation (Morrow et al. 1995) . Moreover, the urinary excretion of the F 2 -isoprostane 8-iso-prostaglandin F 2a was linked with the development of numerous cardiovascular risk factors (Schwedhelm et al. 2004) . Furthermore, an intense staining of superoxide was found in the plaque shoulder, which is rich in macrophages and prone to rupture, clarifying the clinical cardiovascular events (Sorescu et al. 2002) .
Potential sources of ROS and physiological stimuli
There are several potential sources of ROS production. In CVD, the sources include xanthine oxidase, cyclooxygenase, lipoxygenase, cytochrome P450, uncoupled nitric oxide synthases, and NAD(P)H oxidase. They have been identified as sources of ROS generation in all types of vasculature. These sources may contribute to ROS formation, depending on cell type, cellular activation site and disease context (Lakshmi et al. 2009 ).
Various physiological stimuli have the ability to contribute to the pathogenesis of vascular disease and can also induce the formation of ROS. For instance, a variety of agents, including vasoactive agents such as angiotensin-II, endothelin-1 and thrombin have been shown to activate NAD(P)H oxidase. Treatment of vascular smooth muscle cells with angiotensin-II causes an increase in the expression of NAD(P)H oxidase as well as ROS production (Zheng et al. 2003) . Cytokines (interleukin 1b (IL-1b), tumor necrosis factor alpha (TNF-a)), growth factors (platelet-derived growth factor, PDGF; transforming growth factor-b, TGF-b) and hemodynamic forces (shear stress and cyclic stretch) can regulate the expression and/or activity of the vascular NAD(P)H oxidase (Turpaev 2002) .
On the other hand, clinical evidences indicated that ROS were generated intracellularly, and that they are derived from mitochondria. The production of mitochondrial superoxide radicals occurs primarily at two discrete points in the electron-transport chain, namely at complex I (NADH dehydrogenase) and at complex III (ubiquinonecytochrome C reductase) (Finkel and Holbrook 2000) . 
Endothelial dysfunction
Endothelial dysfunction is the initial step in the pathogenesis of atherosclerosis. The impaired endotheliumdependent vasodilation is found in the forearm, coronary, and renal vasculature in patients with CVD (Higashi et al. 2009 ).
Vascular endothelial cells secrete various vasoactive agents, such as the vasodilators nitric oxide (NO) and prostacyclin, and the vasoconstrictors endothelin-1, angiotensin-II, and thromboxane A 2 . A healthy endothelium maintains vascular tone and structure by regulating the balance between vasodilation and vasoconstriction, growth inhibition and growth promotion, antithrombosis and prothrombosis, anti-inflammation and pro-inflammation, and also antioxidation and pro-oxidation (Lüscher 1990) .
It was reported that the possible mechanisms of the impairment of endothelial function in CVD, included abnormalities of shear stress, increased amounts of the endogenous endothelial NO synthase (eNOS) inhibitor asymmetrical dimethylarginine, increased amounts of vasoconstrictors such as angiotensin-II, endothelin-1 and norepinephrine, as well as inactivation of NO by ROS (Sottero et al. 2015) . Increasing evidence reveals an interaction between oxidative stress and endothelial function as shown in Fig. 2 .
To put it simply, the enhanced production of ROS and an attenuated antioxidant system would contribute to endothelial dysfunction in CVD. Decreased NO bioavailability (decreased NO production and/or increased NO inactivation) induces endothelial dysfunction. A balance of endothelium-derived vasodilators, especially NO, and ROS modulates endothelial function. Therefore, an imbalance of NO and ROS, indicated oxidative stress, is involved in endothelial dysfunction through the inactivation of NO (Higashi et al. 2009 ).
ROS and inflammation
Inflammatory reactions induce the production of ROS, and the reverse sequence of these events is also true. Moreover, many components of these reactions interact with a , NOS switches from a coupled state to an uncoupled state and generates O2
2Á with decreased 5,6,7,8-tetrahydrobiopterin (BH4) or L-arginine. Dysfunctional mitochondrial electron-transport chain is another source of
O2
2Á . ROS reduce bioavailability of NO, leading to endothelial dysfunction. ROS influence the activity of a variety of cellular signaling pathways ultimately leading the changes in the expression of redox-sensitive genes, which regulate cellular process involved in cellular apoptosis/death that may be involved in the pathogenesis of cardiovascular disease] Atherosclerotic cardiovascular disease: a review of initiators and protective factors 3 synergistic effect. Global evidences indicated that the developments of atherosclerosis and of the related complications are linked to inflammatory reactions, which are triggered by exogenous or endogenous aggressions (Libby et al. 2002) . The leukocytes adhesion molecules such as vascular cell adhesion molecule-1 (VCAM-1), and chemokines such as monocyte chemoattractant protein (MCP-1) have been shown to prevent leukocytes adhesion and infiltration . The activated leukocytes leave the circulating blood and reach the site of the aggression where they release a large amount of ROS as well as the content of their granules. The granular content is made in a large part by molecules with killing and degradative activities such as myeloperoxidase, elastase, collagenase and lysozyme (Hakim 1993) . The excessive inflammatory reactions are deleterious because they are directed against normal tissues instead or in addition to pathogens. In some cases, the behavior of the phagocytes is modified because they have been primed by inflammatory molecules such as tumor necrosis factor alpha (TNF-a), interleukins or interferons. The priming often leads to a decreased speed of locomotion of the leukocytes with an increased susceptibility to their stimuli, which leads to a premature release by the phagocytes of their killing and degradative factors (Hakim 1993) .
The stimulating effect of cytokines including TNF-a and interleukins, or angiotensin-II on endothelial expression of the VCAM-1 or MCP-1 was suppressed by different ROS scavengers, suggesting that ROS are critical mediators of pro-inflammatory signaling in the endothelium. Some of these redox-sensitive pro-inflammatory signaling pathways could involve the transcription factors NF-jB (Collins and Cybulsky 2001) . NO nitric oxide (NO), ROCK Rho-associated kinase, SOD superoxide dismutase, NADH/NADPH nicotinamide adenine dinucleotide phosphate, ROS reactive oxygen species, HSP heat shock protein, HIF-1 hypoxia-induced factor-1, VEGF vascular endothelial growth factor, eNOS endothelial NO synthase, PI3K phosphatidyl-inositol-3-kinase, MAPK mitogen-activated protein kinase, NF-jB nuclear factor jB, AP-1 plasminogen activator inhibitor-1, VCAM-1 vascular cell adhesion molecule-1, ICAM-1 intracellular adhesion molecule-1, VSMC vascular smooth muscle cell On the other hand, endothelial synthesis of NO Á plays an important role as an anti-inflammatory factor, which reduces endothelial adhesion molecule and chemokine expression. In addition to that, NO Á synthase gene therapy rapidly reduces hypercholesterolemia-induced VCAM-1 expression, and improves monocyte infiltration into the arterial wall (Qian et al. 1999) . It can be concluded that the loss of endothelial NO Á due to elevated ROS production could explain the mechanism whereby oxidative stress promotes the pro-inflammatory phenotype of the endothelium.
ROS and thrombosis
Platelet interaction with the vessel wall serves numerous physiological and pathophysiological functions. This is reflected by the fact that platelets release growth factors, lipid mediators, and cytokines (Krötz et al. 2004 ). Consequently, the regulation of platelet activity plays a role not only for thrombus formation and the regulation of vascular tone, but also for the vascular pathophysiology of angiogenesis and inflammation (Agha et al. 1992) . It is already established that enhanced ROS release from the vascular wall can indirectly affect platelet activity by scavenging NO, thereby decreasing the antiplatelet properties of the endothelium (Loscalzo 2003) . By a direct administration of H 2 O 2 , platelets have also been exposed to superoxide anion generating enzymatic systems such as glucose/glucose oxidase, (hypo-) xanthine/xanthine oxidase, or pyrogallol. Furthermore, several independent studies have shown that superoxide anion reduces the threshold for platelet activation to thrombin, collagen, or arachidonic acid, and may even induce spontaneous aggregation (Krötz et al. 2002) . In all cases, it appeared that superoxide anion, but not OH 2 or H 2 O 2 , mediated the enhanced platelet activity (Krötz et al. 2002) . Pratico et al. (1999) demonstrated that an alternative ROS, OH -, was generated during full blood platelet aggregation induced by collagen, and that the OH -scavenger mannitol partly prevented this aggregation, suggesting that more than one ROS may be involved in enhancing collagen-dependent platelet activation.
In addition to directly activating platelets or decreasing the threshold for platelet activation, superoxide anion reacts with platelet or endothelium-derived NO to ONOO -, which is of particular importance for vascular thrombosis. This is primarily caused by the decreased bioavailability of NO as a potent inhibitor of platelet activation. It is not surprising, therefore, that the antithrombotic effect of NO is lost either when ROS are exogenously added to the system or when they are scavenged by superoxide dismutase (superoxide dismutase converted the superoxide anion to H 2 O 2 ). It is, however, likely that ONOO -, being a highly reactive molecule, exerts additional effects on platelets (Radomski et al. 1987) .
ROS activates matrix metalloproteinases: relevance to plaque instability
Matrix metalloproteinases (MMPs) constitute a family of zinc-containing endopeptidases that is organized into three basic, distinctive, well-conserved, and structurally distinct domains: an amino acid terminal propeptide, a catalytic domain, and a hemopexin-like domain at carboxyl terminal (Massova et al. 1998 ). Metalloproteinases play a key role in the responses of cells to their microenvironment. By producing proteolytic degradation or activation of cell surface and ECM proteins, they can modulate both cellcell and cell-ECM interactions, which influence cell differentiation, migration, proliferation, and survival (Baker et al. 2002) .
Matrix metalloproteinases and tissue inhibitors of MMPs (TIMPs) are the main determinants of tissue remodeling in both physiological and pathological processes (Patruno et al. 2012) . MMPs play an important role in atherosclerosis by degrading the extracellular matrix, which results in cardiovascular remodeling. Recent studies have identified enhanced expression of MMPs in the atherosclerotic lesion and their contribution to the weakening of the vascular wall by degrading the extracellular matrix. The transcription, enzyme processing, and specific inhibition of MMPs by TIMPs regulate these effects. These processes are also modified by inflammatory cytokines and cell-cell contact signaling (Watanabe and Ikeda 2004) .
Both animal experiments and clinical sample analysis have shown that balance in expression and activation of MMPs and inhibition by TIMPs is critical for the development of stenotic and aneurysmal change. Polymorphism in the MMP gene promoter contributes to inter-individual differences in susceptibility to CHD. The development of therapeutic drugs specifically targeting MMPs may thus be useful for the prevention of atherosclerotic lesion progression, plaque rupture, and restenosis (Watanabe and Ikeda 2004) .
The expression of MMP-2 (gelatinase A: degrades collagen IV) and MMP-9 (gelatinase B: acts on collagen I fibers) that are secreted by macrophages and vascular monocytes, is increased in the rupture-prone shoulders of atherosclerotic plaques (Galis et al. 1994) . Notably, ROS have been shown to importantly modulate MMPs that could contribute to lesion instability (Rajagopalan et al. 1996) . Furthermore, cyclic strain-induced MMP-2 expression on vascular smooth muscle cells was dependent on the activation of the oxidant enzyme NAD(P)H oxidase (Grote et al. 2003) .
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Lipoproteins and oxidation
The association between low-density lipoprotein cholesterol (LDL) and atherosclerosis has been established based, in part, on an experiment of nature. Familial hypercholesterolemia is an autosomal dominant disorder that affects about 1 in 500 persons from the general population. Heterozygotes for this disease manifest a two-to fivefold elevation in plasma LDL cholesterol that is due to a functional impairment of the LDL receptor, resulting in a defect in LDL clearance. Homozygotes for this disorder demonstrate a four-to sixfold elevation in plasma cholesterol that produces precocious atherosclerosis. In heterozygotes, 85 % of individuals have experienced a myocardial infarction by the age of 60, and this age is reduced to 15 years in patients homozygous for the disease (Gotto and Farmer 1988) . In the general population, the CVD risk from increased LDL cholesterol is supported by observations that cholesterol-lowering therapy greatly diminishes the clinical manifestations of atherosclerosis, particularly since the advent of inhibitors of 3-hydroxy-3-methylglutaryl coenzyme A reductase (i.e., statins) that profoundly lower LDL cholesterol (Gotto and Grundy 1999) . The oxidation of lipoproteins, particularly the LDL, has been approved as the major risk factor in the development of atherosclerosis (Steinberg 2002) . The oxidation of LDL in the vessel wall leads to an inflammatory cascade that activates many atherogenic pathways, including the unregulated uptake of oxidized LDL (OxLDL) by scavenger receptors of monocyte-derived macrophages leading to foam cell formation. The accumulation of foam cells leads to fatty streak formation, which is the earliest visible atherosclerotic lesion (Libby 2012) .
It consists of cholesterol ester-laden cells that are mostly derived not only from circulating monocytes, which penetrated through the endothelial layer, but also from modified smooth muscle cells. Foam cell necrosis and/or apoptosis and continued accumulation of oxidized lipid in the extracellular space eventually lead to atheroma formation. The complex interplay of oxidized lipids, inflammatory process, endothelial dysfunction, and platelets activation and thrombus ultimately leads to plaque progression and/or disruption, which in turn leads to adverse clinical events. In addition to that, inflammatory cells play an important role throughout all past events, which results in atherosclerotic lesion (Libby 2012 ).
LDL oxidation
Each particle of LDL contains about 700 molecules of phospholipids, 600 of free cholesterol, 1600 of cholesterol ester, 185 of triglycerides and one copy of apoprotein B-100, which in turn is made of 4536 amino acids residues.
The protein and lipid portions of LDL are sensitive to oxidation (Taleb et al. 2011) . In plasma, LDL is stable, but once it has been purified and isolated, it begins to oxidize rapidly. Divalent cations such as copper (Cu 2? ) are able to catalyze oxidative modification of LDL, which becomes a ligand for the acetyl LDL receptor, leading to foam cell formation (Steinbrecher et al. 1984) .
Atherogenic properties of oxidized LDL (OxLDL)
According to Bourassa and Tardif (2006) , the OxLDL has biological properties that make it more atherogenic than native LDL.
-OxLDL has enhanced uptake by macrophages leading to foam cell formation. -Products of OxLDL are chemotractic for monocytes and T cell as well as inhibit the motility of tissue macrophages. -Due to oxidized sterols, products of OxLDL are cytotoxic and can induce apoptosis. -OxLDL is mitogenic (influence cell division) for smooth muscle cells and macrophages. -OxLDL can alter gene expression of vascular cells, such as induction of MCP-1, interleukins, and adhesion molecules. -OxLDL and its products can induce pro-inflammatory genes. -Products of OxLDL can lead to plaque disruption, thus being involved in acute coronary syndromes.
Response-to-retention hypothesis of atherosclerosis
The hypothesis submits that the lipoprotein retention is the inciting event for atherosclerosis (Fig. 3) . Within 2 h of injecting LDL into rabbits, arterial retention of LDL and its microaggregates can be observed (Nievelstein et al. 1991) . It is estimated that about 85 % of subendothelial lipoprotein delivery is the result of transcytosis, and this process is restricted to particles less than 70 nm in diameter (Simionescu and Simionescu 1993) . This size restriction is important as it suggests that lipoprotein lipase activity is needed for triacylglycerol-rich lipoproteins to reach the subendothelial space (Stocker and Keaney 2004) . The retention of lipoproteins within the arterial wall, however, appears tightly linked to components of the extracellular matrix. Apolipoprotein B-100, the single protein associated with LDL, is retained within the arterial wall in close association with arterial proteoglycans (Camejo et al. 1993 ). This interaction is mediated by specific residues (3359-3369) that, when mutated, protect experimental animals against the development of atherosclerosis (Borén et al. 1998) . Apolipoprotein B-48, which appears to be equally atherogenic as apolipoprotein B-100 in mice (Véniant et al. 1997) , also binds avidly to proteoglycans, and this interaction is mediated by residues 84-94 of apolipoprotein B-48 (Flood et al. 2002) . Thus, these data support an important role for proteoglycan binding in the retention of apolipoprotein B-containing lipoproteins in the early stages of atherosclerosis.
Factors improve cardiac function
Alongside NAD(P)H oxidase, monitoring of SERCA2a function, or of hepatic apoE expression, has been confirmed to lower the risk of preexisting atherosclerotic insults.
SERCA2a
The cardiac Ca 2? ATPase (SERCA2a) of the sarcoplasmic reticulum (SR) plays a dominant role in lowering cytoplasmic calcium levels during relaxation (Nakayama et al. 2003) . Contraction and relaxation in cardiac myocytes are tightly regulated by intrinsic mechanisms that govern the sequential rise and fall of cytosolic Ca 2? . During depolarization, Ca 2? entry through the L-type Ca 2? channels triggers the release of Ca 2? from the SR through ryanodine receptors, resulting in activation of the contractile proteins. In human cardiomyocytes, the removal of Ca 2? from the cytoplasm is governed mainly by the SERCA2a pump and to a lesser extent the Na/Ca exchanger (Arai et al. 1994) . The isolated cardiomyocytes from failing human hearts are Fig. 3 Response-to-retention hypothesis of atherosclerosis. Mild to moderate hyperlipidemia causes lesion development in specific sites within the arterial tree characterized by local synthesis of apolipoprotein B-retentive molecules such as biglycan and decorin. The figure shows the initial stages of arterial lipoprotein delivery, retention, and efflux (1-5). Accumulation (5) is thought to result from both apolipoprotein B-100 motifs that mediate proteoglycan binding and arterial factors such as secretory sphingomyelinase that facilitate lipoprotein aggregation. The accumulation of apolipoprotein B-100-containing lipoproteins within the arterial wall is thought to further trigger a proinflammatory cascade (6-13). Lipoprotein oxidation (not shown) may or may not be part of these responses. Similar to LDL, apolipoprotein B-48-containing chylomicron remnants may also bind to proteoglycans via residues 84-94 of the apolipoprotein and hence be retained within the arterial wall (not shown). Modified from Proctor et al. (2002) and adapted from Stocker and Keaney (2004) Atherosclerotic cardiovascular disease: a review of initiators and protective factors 7 characterized by contractile dysfunction, and paralleled by abnormal Ca 2? homeostasis, such as reduced SR Ca 2?
release (Davies et al. 1995) . In the failing heart, the decrease in SR Ca 2? load has been linked to a decrease in SERCA2a function (Hasenfuss et al. 1994) . Stimulation of SERCA2a is thought as an innovative approach to the therapy of congestive heart failure (Ferrari et al. 2007 ). SERCA2a has also been identified as an important effector of NO Á action in vascular cells. NO Á function is impaired in a variety of CVD, including diabetes, hypercholesterolemia, and atherosclerosis, which are all associated with SERCA2a dysfunction caused by increased oxidants in these diseases. Targeting the oxidant sources in vascular diseases to prevent SERCA2a from being oxidized and/or increasing the expression of SERCA2a may improve vascular disease development (Tong et al. 2010 ).
Hepatic apoE expression
Apolipoprotein E (apoE) has roles beyond lipoprotein metabolism. Structural differences in apoE isoforms impact cardiovascular, neurological, and infectious diseases. It was identified in triglyceride-rich lipoproteins and induced by cholesterol feeding in animal models and humans. The three common isoforms (apoE2, apoE3, and apoE4) are encoded by a gene on chromosome 19. ApoE2 and apoE4 were shown to be involved in lipid transport and CVD (Mahley and Rall 2000) . It has been established that apoE plays a role in promoting the hepatic secretion of very low-density lipoprotein triglycerides (vLDL-Trig) (Mahley and Huang 1999) . The vLDL-Trig secretion is impaired in apoE-deficient mice compared to wild-type mice and was not normalized by extrahepatic apoE expression (Kuipers et al. 1997) . In mice, the livers of apoE-deficient have increased content of triglycerides as well as cholesterol (Maugeais et al. 2000) . Meaning that, apoE is the critical ligand in the plasma clearance of triglyceride-and cholesterol-rich lipoproteins (chylomicron remnants, vLDL, intermediate density lipoproteins, and a subclass of HDL) (Mahley et al. 2009 ).
Conclusion
This review discussed the two major mechanisms involved in initiating CVD (production of ROS and lipoprotein oxidation), and two protective factors that may lower the risk of preexisting atherosclerotic insults (SERCA2a and hepatic apoE expression). The experimental and clinical studies in CVD patients confirmed that there is a relationship between cardiovascular risk factors and the increased vascular production of ROS and lipoprotein oxidation. The involvement of ROS in normal vascular cells signaling allows them to regulate vascular contraction and relaxation, and is associated with decreased production of anti-inflammatory and anti-atherogenic nitric oxide. ROS is also involved in platelets interaction with vessel wall influencing them for the development of thrombosis. Moreover, including the unregulated uptake of OxLDL by scavenger receptors of monocyte-derived macrophages, the oxidation of LDL in the vessel wall leads to inflammatory cascade that activates many atherogenic pathways leading to foam cell formation and accumulation, and thus fatty streak formation, which is the earliest visible atherosclerotic lesion. On the other hand, the removal of Ca 2? from the cytoplasm is governed mainly by the SERCA2a pump; SERCA2a improves cardiovascular function by regulating the cardiac contractile function and NO Á action in vascular cells. Finally, apoE plays a protective role in promoting the hepatic secretion of vLDL-Trig that helps in lipid transport and plasma clearance of triglycerideand cholesterol-rich lipoproteins.
